Restricted accessResearch articleFirst published online 2025-08
Therapeutic Intervention of an Intranasally Administered Monoclonal Antibody Targeting the SARS-CoV-2 Omicron Spike Protein Against SARS-CoV-2 Omicron Infection in Mice
SARS-CoV-2 has evolved into several variants of concern, with Omicron and its subvariants currently being the most prevalent. Previously, we developed a mouse monoclonal antibody (m1E3H12 mAb) specific to the receptor binding domain of SARS-CoV-2 Omicron spike protein, and the mAb showed neutralizing activity against SARS-CoV-2 Omicron BA.1 and its subvariants BA.5, BQ.1.1, and XBB. Here, we showed that the mAb provided protection against SARS-CoV-2 Omicron infection in K18-hACE2 transgenic mice when administered intranasally. The mAb treatment reduced viral loads in both the brain and lungs. Additionally, the elevated levels of RANTES (CCL5) and MIP-3 alpha (CCL20) in the brain following SARS-CoV-2 Omicron infection showed a decreasing trend after mAb treatment. Therefore, we conclude that our mAb specific to SARS-CoV-2 Omicron spike protein has the potential to be applied as therapeutics against SARS-CoV-2 Omicron BA.1 and its subvariants BA.5, BQ.1.1, and XBB.
Get full access to this article
View all access options for this article.
References
1.
AoD, HeX, HongW, et al.The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants. MedComm (2020), 2023; 4(2):e239; doi: 10.1002/mco2.239
2.
ArimaY, HaradaM, KamimuraD, et al.Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell, 2012; 148(3):447–457; doi: 10.1016/j.cell.2012.01.022
3.
BaekK, KimD, KangBM, et al.Parental Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) predominates over coinfected SARS-CoV-2 delta, producing less lethal variants in a long-term replication mouse model. J Med Virol, 2024a;96(11):e70072; doi: 10.1002/jmv.70072
4.
BaekK, KimD, KimJ, et al.Analysis of SARS-CoV-2 omicron mutations that emerged during long-term replication in a lung cancer xenograft mouse model. Virus Genes, 2024b;60(3):251–262; doi: 10.1007/s11262-024-02067-6
5.
BaekK, MaharjanS, AkauliyaM, et al.Comparison of vaccination efficacy using live or ultraviolet-inactivated influenza viruses introduced by different routes in a mouse model. PLoS One, 2022; 17(10):e0275722; doi: 10.1371/journal.pone.0275722
6.
Centers for Disease Control and Prevention (CDC). COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2024, July 24. Available from: https://covid.cdc.gov/covid-data-tracker
7.
DongW, MeadH, TianL, et al.The K18-human ACE2 transgenic mouse model recapitulates non-severe and severe COVID-19 in response to an infectious dose of the SARS-CoV-2 virus. J Virol, 2022; 96(1):e0096421; doi: 10.1128/JVI.00964-21
8.
DutyJA, KrausT, ZhouH, et al.Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants. Med, 2022; 3(10):705–721; doi: 10.1016/j.medj.2022.08.002
9.
FoxJG, DavissonMT, QuimbyFW, et al.The Mouse in Biomedical Research, 2nd ed. London, UK: Academic Press: 2007.
10.
GonçalvesR, CoutoJ, FerreirinhaP, et al.SARS-CoV-2 variants induce distinct disease and impact in the bone marrow and thymus of mice. iScience, 2023; 26(2):105972; doi: 10.1016/j.isci.2023.105972
11.
GouldJC, CarvajalI, DavidsonT, et al.Bioavailability of protein therapeutics in rats following inhalation exposure: Relevance to occupational exposure limit calculations. Regul Toxicol Pharmacol, 2018; 100:35–44; doi: 10.1016/j.yrtph.2018.10.003
12.
GuptaA, Gonzalez-RojasY, JuarezE, et al.; COMET-ICE Investigators. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med, 2021; 385(21):1941–1950; doi: 10.1056/NEJMoa2107934
13.
HalweS, KupkeA, VanshyllaK, et al.Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection. Viruses, 2021; 13(8):1498; doi: 10.3390/v13081498
14.
HuJ, YangZ, LiX, et al.C-C motif chemokine ligand 20 regulates neuroinflammation following spinal cord injury via Th17 cell recruitment. J Neuroinflammation, 2016; 13(1):162; doi: 10.1186/s12974-016-0630-7
15.
JakiT, WolfseggerMJ. Estimation of pharmacokinetic parameters with the R package PK. Pharm Stat, 2011; 10(3):284–288; doi: 10.1002/pst.449
16.
JiaJ, YinZ, ZhangX, et al.Feasibility studies of nebulized SARS-CoV-2 neutralizing antibody in mice and cynomolgus monkeys. Pharm Res, 2022; 39(9):2191–2201; doi: 10.1007/s11095-022-03340-9
17.
KangBM, KimD, KimJ, et al.Analysis of SARS-CoV-2 mutations after Nirmatrelvir Treatment in a lung cancer Xenograft mouse model. Biomol Ther (Seoul), 2024; 32(4):481–491; doi: 10.4062/biomolther.2023.195
18.
KhalilBA, ElemamNM, MaghazachiAA. Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J, 2021; 19:976–988; doi: 10.1016/j.csbj.2021.01.034
19.
KimD, KimJ, AnS, et al.In vitro and in vivo suppression of SARS-CoV-2 replication by a modified, short, cell-penetrating peptide targeting the C-terminal domain of the viral spike protein. J Med Virol, 2023a;95(3):e28626; doi: 10.1002/jmv.28626
20.
KimD, KimJ, KimM, et al.Analysis of spike protein variants evolved in a novel in vivo long-term replication model for SARS-CoV-2. Front Cell Infect Microbiol, 2023b;13:1280686; doi: 10.3389/fcimb.2023.1280686
21.
KimD, KimM, KimJ, et al.A mouse xenograft long-term replication yields a SARS-CoV-2 Delta mutant with increased lethality. J Med Virol, 2024a;96(2):e29459; doi: 10.1002/jmv.29459
22.
KimJ, HwangSY, KimD, et al.Abiraterone acetate attenuates SARS-CoV-2 replication by interfering with the structural nucleocapsid protein. Biomol Ther (Seoul), 2022; 30(5):427–434; doi: 10.4062/biomolther.2022.037
23.
KimJ, KimS, ParkS, et al.Production of a monoclonal antibody targeting the SARS-CoV-2 Omicron spike protein and analysis of SARS-CoV-2 Omicron mutations related to monoclonal antibody resistance. Microbes Infect, 2024b;27(3):105461; doi: 10.1016/j.micinf.2024.105461
24.
LeiC, YangJ, HuJ, et al.On the calculation of TCID50 for quantitation of virus infectivity. Virol Sin, 2021; 36(1):141–144; doi: 10.1007/s12250-020-00230-5
25.
MaxwellAJ, DingJ, YouY, et al.Identification of key signaling pathways induced by SARS-CoV2 that underlie thrombosis and vascular injury in COVID-19 patients. J Leukoc Biol, 2021; 109(1):35–47; doi: 10.1002/JLB.4COVR0920-552RR
26.
NatekarJP, PathakH, StoneS, et al.Differential pathogenesis of SARS-CoV-2 variants of concern in human ACE2-expressing mice. Viruses, 2022; 14(6):1139; doi: 10.3390/v14061139
27.
ParkS, KimD, KimJ, et al.SARS-CoV-2 infection induces expression and secretion of lipocalin-2 and regulates iron in a human lung cancer xenograft model. BMB Rep, 2023; 56(12):669–674; doi: 10.5483/BMBRep.2023-0177
28.
ParrayHA, ShuklaS, PerweenR, et al.Inhalation monoclonal antibody therapy: A new way to treat and manage respiratory infections. Appl Microbiol Biotechnol, 2021; 105(16–17):6315–6332; doi: 10.1007/s00253-021-11488-4
29.
PattersonBK, SeethamrajuH, DhodyK, et al.CCL5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. Int J Infect Dis, 2021; 103:25–32; doi: 10.1016/j.ijid.2020.10.101
30.
PumA, EnnemoserM, AdageT, et al.Cytokines and chemokines in SARS-CoV-2 infections-therapeutic strategies targeting cytokine storm. Biomolecules, 2021; 11(1):91; doi: 10.3390/biom11010091
31.
RadvakP, KwonHJ, KosikovaM, et al.SARS-CoV-2 B.1.1.7 (Alpha) and B.1.351 (Beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains. Nat Commun, 2021; 12(1):6559; doi: 10.1038/s41467-021-26803-w
32.
TakashitaE, YamayoshiS, SimonV, et al.Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med, 2022; 387(5):468–470; doi: 10.1056/NEJMc2207519
33.
ToussiSS, HammondJL, GerstenbergerBS, et al.Therapeutics for COVID-19. Nat Microbiol, 2023; 8(5):771–786; doi: 10.1038/s41564-023-01356-4
34.
WeinreichDM, SivapalasingamS, NortonT, et al.; Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med, 2021; 384(3):238–251; doi: 10.1056/NEJMoa2035002
35.
WinklerES, BaileyAL, KafaiNM, et al.SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol, 2020; 21(11):1327–1335; doi: 10.1038/s41590-020-0778-2
WuG, KimD, KimJN, et al.A Mucin1 C-terminal subunit-directed monoclonal antibody targets overexpressed Mucin1 in breast cancer. Theranostics, 2018; 8(1):78–91; doi: 10.7150/thno.21278
38.
ZhouT, WangL, MisasiJ, et al.Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science, 2022; 376(6591):eabn8897; doi: 10.1126/science.abn8897
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
